APPLICATION
ANDA214618
TYPE
ANDA
ORIGINAL APPROVAL
2023-03-06
LATEST ACTION
2026-04-27
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription
Products
LENALIDOMIDEPrescription
LENALIDOMIDE 2.5MG · CAPSULE · ORAL
Approval history
2026-04-27REMS · Supplement 6AP
2023-03-24REMS · Supplement 1AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.